Submitted:
31 December 2023
Posted:
02 January 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
3.1. Study population and mitral valve features
3.2. NLR and PLR
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Essayagh, B.; Sabbag, A.; Antoine, C.; Benfari, G.; Yang, L.T.; Maalouf, J.; Asirvatham, S.; Michelena, H.; Enriquez-Sarano, M. Presentation and Outcome of Arrhythmic Mitral Valve Prolapse. J Am Coll Cardiol 2020, 76, 637–649. [CrossRef]
- Miller, M.A.; Adams, D.H.; Pandis, D.; Robson, P.M.; Pawale, A.; Pyzik, R.; Liao, S.L.; El-Eshmawi, A.; Boateng, P.; Garg, J.; et al. Hybrid Positron Emission Tomography/Magnetic Resonance Imaging in Arrhythmic Mitral Valve Prolapse. JAMA Cardiol 2020, 5, 1000–1005. [CrossRef]
- Silvestre-Roig, C.; Braster, Q.; Ortega-Gomez, A.; Soehnlein, O. Neutrophils as Regulators of Cardiovascular Inflammation. Nat Rev Cardiol. [CrossRef]
- Song, M.; Graubard, B.I.; Rabkin, C.S.; Engels, E.A. Neutrophil-to-Lymphocyte Ratio and Mortality in the United States General Population. Sci Rep 2021, 11. [CrossRef]
- Zhai, G.; Wang, J.; Liu, Y.; Zhou, Y. Platelet-Lymphocyte Ratio as a New Predictor of in-Hospital Mortality in Cardiac Intensive Care Unit Patients. Sci Rep 2021, 11. [CrossRef]
- Davison, B.A.; Takagi, K.; Edwards, C.; Adams, K.F.; Butler, J.; Collins, S.P.; Dorobantu, M.I.; Ezekowitz, J.A.; Filippatos, G.; Greenberg, B.H.; et al. Neutrophil-to-Lymphocyte Ratio and Outcomes in Patients Admitted for Acute Heart Failure (As Seen in the BLAST-AHF, Pre-RELAX-AHF, and RELAX-AHF Studies). Am J Cardiol 2022, 180, 72–80. [CrossRef]
- Yalim, Z.; Ersoy, İ. Evaluation of Inflammation Markers in Mitral Valve Prolapse. Arch Cardiol Mex 2022, 92, 181–188. [CrossRef]
- Aabel, E.W.; Chivulescu, M.; Lie, Ø.H.; Hopp, E.; Gjertsen, E.; Ribe, M.; Helle-Valle, T.M.; Edvardsen, T.; Hegbom, F.; Dejgaard, L.A.; et al. Ventricular Arrhythmias in Arrhythmic Mitral Valve Syndrome—a Prospective Continuous Long-Term Cardiac Monitoring Study. Europace 2023, 25, 506. [CrossRef]
- Forget, P.; Khalifa, C.; Defour, J.P.; Latinne, D.; Van Pel, M.C.; De Kock, M. What Is the Normal Value of the Neutrophil-to-Lymphocyte Ratio? BMC Res Notes 2017, 10, 1–4. [CrossRef]
- Fest, J.; Ruiter, R.; Ikram, M.A.; Voortman, T.; Van Eijck, C.H.J.; Stricker, B.H. Reference Values for White Blood-Cell-Based Inflammatory Markers in the Rotterdam Study: A Population-Based Prospective Cohort Study. Sci Rep 2018, 8. [CrossRef]
- Buonacera, A.; Stancanelli, B.; Colaci, M.; Malatino, L. Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases. Int J Mol Sci 2022, 23. [CrossRef]
- Markanday, A. Acute Phase Reactants in Infections: Evidence-Based Review and a Guide for Clinicians. Open Forum Infect Dis 2015, 2. [CrossRef]
- Grune, J.; Yamazoe, M.; Nahrendorf, M. Electroimmunology and Cardiac Arrhythmia. Nat Rev Cardiol 2021, 18, 547–564. [CrossRef]
- Sriram, C.S.; Syed, F.F.; Ferguson, M.E.; Johnson, J.N.; Enriquez-Sarano, M.; Cetta, F.; Cannon, B.C.; Asirvatham, S.J.; Ackerman, M.J. Malignant Bileaflet Mitral Valve Prolapse Syndrome in Patients with Otherwise Idiopathic Out-of-Hospital Cardiac Arrest. J Am Coll Cardiol 2013, 62, 222–230. [CrossRef]
- Basso, C.; Perazzolo Marra, M.; Rizzo, S.; De Lazzari, M.; Giorgi, B.; Cipriani, A.; Frigo, A.C.; Rigato, I.; Migliore, F.; Pilichou, K.; et al. Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death. Circulation 2015, 132, 556–566. [CrossRef]
- Afari, M.E.; Bhat, T. Neutrophil to Lymphocyte Ratio (NLR) and Cardiovascular Diseases: An Update. Expert Rev Cardiovasc Ther 2016, 14, 573–577. [CrossRef]



| NLR < 5.6 (n=53) | NLR ≥ 5.6 (n=12) | p-value | NLR < 3.92 (n=48) | NLR ≥ 3.92 (n=17) | p-value | ||
|---|---|---|---|---|---|---|---|
| Age at echo (years) | 68 (56-75) | 78 (66-81) | 0.03 | 68 (57-75) | 76 (63-81) | 0.09 | |
| Female | 36 (68) | 4 (33) | 0.046 | 33 (69) | 7 (41) | 0.08 | |
| African American | 7 (13) | 1 (8) | 1.00 | 7 (15) | 1 (6) | 0.67 | |
| Hypertension | 21 (40) | 7 (58) | 0.33 | 19 (40) | 9 (53) | 0.40 | |
| Diabetes | 3 (6) | 1 (8) | 0.57 | 3 (6) | 1 (6) | 1.00 | |
| Dyslipidemia | 12 (23) | 4 (33) | 0.47 | 10 (21) | 6 (35) | 0.33 | |
| Atrial fibrillation | 17 (32) | 5 (42) | 0.52 | 14 (29) | 8 (47) | 0.24 | |
| Coronary artery disease | 9 (17) | 2 (17) | 1.00 | 8 (17) | 3 (18) | 1.00 | |
| Heart failure | 4 (8) | 5 (42) | 0.008 | 3 (6) | 6 (35) | 0.007 | |
| Beta blocker | 20 (38) | 7 (58) | 0.21 | 18 (38) | 9 (53) | 0.39 | |
| Calcium channel blocker | 4 (8) | 0 (0) | 1.00 | 4 (8) | 0 (0) | 0.57 | |
| Angiotensin receptor blocker | 6 (11) | 2 (17) | 0.63 | 6 (13) | 2 (12) | 1.00 | |
| ACE inhibitor | 8 (15) | 3 (25) | 0.41 | 7 (15) | 4 (24) | 0.46 | |
| Class I or III antiarrhythmic | 6 (11) | 1 (8) | 1.00 | 5 (10) | 2 (12) | 1.00 | |
| Aldosterone antagonist | 1 (2) | 1 (8) | 0.34 | 1 (2) | 1 (6) | 0.46 | |
| ECG T-wave inversion | 16 (30) | 4 (33) | 1.00 | 16 (33) | 4 (24) | 0.55 | |
| Moderate-severe mitral regurgitation | 19 (36) | 6 (50) | 0.51 | 12 (25) | 6 (35) | 0.53 | |
| Myxomatous valve morphology | 15 (28) | 3 (25) | 1.00 | 16 (33) | 9 (53) | 0.25 | |
| Bileaflet prolapse | 18 (34) | 6 (50) | 0.33 | 13 (27) | 11 (65) | 0.009 | |
| Mitral annular disjunction | 10 (19) | 2 (17) | 1.00 | 8 (17) | 4 (24) | 0.72 | |
| LV ejection fraction (%) | 55 (55-60) | 57.5 (55-62.5) | 0.62 | 55 (55-60) | 57.5 (55-62.5) | 0.60 | |
| LV end-diastolic diameter (cm) | 4.6 (4.2-5.0) | 4.5 (4.0-4.6) | 0.14 | 4.6 (4.2-4.9) | 4.5 (4.1-5.0) | 0.82 | |
| *Values are n (%) or median (interquartile range). p-values calculated using Fisher’s exact test or Wilcoxon rank-sum test, where appropriate. ACE = angiotensin-converting enzyme; LV = left ventricle; MAD = mitral annular disjunction; NLR = neutrophil:lymphocyte ratio | |||||||
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).